title stringlengths 1 1.19k | keywords stringlengths 0 668 | concept stringlengths 0 909 | paragraph stringlengths 0 61.8k | PMID stringlengths 10 11 |
|---|---|---|---|---|
Declarations | PMC9957611 | |||
Ethics approval and consent to participate | Ethical approval was provided by the Ghana Health Service Ethics Review Committee (protocol ID no: GHS-ERC 009/11/20), and the Institutional Review Board of KBTH (protocol ID no: KBTH-IRB 000175/2021). Prior to any study procedures, all participants gave written informed consent in person. The study was conducted in li... | PMC9957611 | ||
Consent for publication | Consent for publication is not applicable. | PMC9957611 | ||
Competing interests | "The authors declare that they have no competing interests". | PMC9957611 | ||
References | PMC9957611 | |||
Subject terms | SARS-CoV-2 infection | MAY, SARS-COV-2 INFECTION | ABO blood type has been reported as a potential factor influencing SARS-CoV-2 infection, but so far mostly in studies that involved small samples, selected population and/or used PCR test results. In contrast our study aimed to assess the association between ABO blood types and SARS-CoV-2 infection using seroprevalence... | PMC10034870 |
Introduction | infection, SARS-CoV-2 infection | COVID-19 (CORONAVIRUS DISEASE 2019), SARS-COV-2 INFECTION, DISEASE, INFECTION, CORONAVIRUS, SEVERE ACUTE RESPIRATORY SYNDROME | Since 2020, the world has been struggling with the COVID-19 (Coronavirus Disease 2019) pandemic caused by the SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). The research community has mobilized to identify potential risk factors associated with SARS-CoV-2 infection and COVID-19 severity, in an effort to ... | PMC10034870 |
Methods | MAY | The SAPRIS (“SAnté, Perception, pratiques, Relations et Inégalités Sociales en population générale pendant la crise COVID-19”) study was set up in April 2020 to investigate various aspects of the COVID-19 crisis (COVID-19 infection/diagnosis and experience of lockdown), based on a consortium of existing French prospect... | PMC10034870 | |
Ethics approval and informed consent | The SAPRIS-SERO study (registered #NCT04392388) was conducted in accordance with the relevant guidelines and regulations and was approved by the ethics committee CPP Sud-Méditerranée III on April 27th 2020 and by the CNIL #920,193. All participants provided written or electronic informed consent for participation in ea... | PMC10034870 | ||
Acknowledgements | The authors warmly thank all the volunteers of the Constances, E3N-E4N and NutriNet-Santé cohorts for their continuous participation in the study and for participating in the SAPRIS-SERO project. We thank the CEPH-Biobank staff for their adaptability and the quality of their work. In the virology department, we thank D... | PMC10034870 | ||
Author contributions | The authors’ contributions were as follows – M.D.T., M.T. conceptualized the study and defined the analytical strategy; F.S.E.: performed statistical analyses; M.D.T. supervised statistical analyses and drafted the manuscript; M.T.: supervised statistical analyses and writing; F.S.E., N.D.P., Y.E., J.A., P.G., S.H., G.... | PMC10034870 | ||
Funding | NutriNet-Santé, Cancer | CANCER | The SAPRIS/SAPRIS-SERO projects received funding from ANR (Agence Nationale de la Recherche, #ANR-20-COVI-000, #ANR-10-COHO-06), Fondation pour la Recherche Médicale (#20RR052-00), and Inserm (Institut National de la Santé et de la Recherche Médicale, #C20-26). The NutriNet-Santé cohort study was supported by the follo... | PMC10034870 |
Data availability | Data from the study are protected under the protection of health data regulation set by the French National Commission on Informatics and Liberty (Commission Nationale de l’Informatique et des Libertés, CNIL). The data can be made available upon reasonable request to the corresponding author (m.deschasaux@eren.smbh.uni... | PMC10034870 | ||
Competing interests | The authors declare no competing interests. | PMC10034870 | ||
References | PMC10034870 | |||
Background | CHB, chronic hepatitis B | CHB, HEPATITIS B VIRUS (HBV) | Hepatitis B virus (HBV) core protein-targeting antivirals (CpTAs) are promising therapeutic agents for treating chronic hepatitis B (CHB). In this study, the antiviral activity, pharmacokinetics (PK), and tolerability of ZM-H1505R (Canocapavir), a chemically unique HBV CpTA, were evaluated in patients with CHB. | PMC10022191 |
Methods | CHB | CHB | This study was a double-blind, randomized, placebo-controlled phase 1b trial in Chinese CHB patients. Noncirrhotic and treatment-naive CHB patients were divided into three cohorts (10 patients per cohort) and randomized within each cohort in a ratio of 4:1 to receive a single dose of 50, 100, or 200 mg of Canocapavir o... | PMC10022191 |
Results | ADVERSE REACTIONS, ADVERSE EVENTS | Canocapavir was well tolerated, with the majority of adverse reactions being grade I or II in severity. There were no serious adverse events, and no patients withdrew from the study. Corresponding to 50, 100, and 200 mg doses of Canocapavir, the mean plasma trough concentrations of the drug were 2.7-, 7.0-, and 14.6-fo... | PMC10022191 | |
Conclusions | CHB, HBV infection | CHB | Canocapavir treatment is tolerated with efficacious antiviral activity in CHB patients, supporting its further development in treating HBV infection. | PMC10022191 |
Trial registration | ClinicalTrials.gov, number NCT05470829). | PMC10022191 | ||
Supplementary Information | The online version contains supplementary material available at 10.1186/s12916-023-02814-w. | PMC10022191 | ||
Keywords | PMC10022191 | |||
Background | infection, deaths, viral infections | HEPATITIS B, VIRUS, VIRAL INFECTION, INFECTION, CHRONIC HEPATITIS, CHB | Chronic hepatitis caused by hepatitis B virus (HBV) infection is a major global health problem, with an estimated 0.6–1 million deaths per year [Developing drugs targeting different HBV life cycle steps has become a critical approach for treating viral infections, such as CHB [HBV core protein-targeting antivirals (CpT... | PMC10022191 |
Methods | PMC10022191 | |||
Study design | MAY | This was a randomized, open-label, placebo-controlled, phase 1b study (Clinical Trial Registration Number: NCT05470829; Chinese Clinical Trial Registration Number: CTR20210686), which was conducted at the Phase I Clinical Research Center, The First Hospital of Jilin University (Jilin, China), during the period from May... | PMC10022191 | |
Participants | The main inclusion criteria of the participants were as follows: 1) adult subjects aged 18–65 years old who were treatment-naive or had terminated their treatment at least six months for nucleoside analog use or at least one year for interferon use prior to screening; 2) showing serum HBV DNA ≥ 2 × 10 | PMC10022191 | ||
Procedures | PMC10022191 | |||
Randomization and blinding | CHB | CHB | A total of 30 CHB patients were recruited in this study and were randomly assigned into three cohorts (Design of this study | PMC10022191 |
Assessment of adverse reactions and drug tolerability | toxicity | ADVERSE EVENTS, ADVERSE EVENT, ADVERSE REACTIONS, ADVERSE EVENT | To examine possible adverse events (AEs) and adverse reactions (an adverse event is definitely, probably, or possibly related to the drug) in this study, the recruited patients underwent regular clinical laboratory testing, 12-lead electrocardiograms, examination of vital signs, abdominal ultrasound, and regular physic... | PMC10022191 |
Pharmacokinetics | BLOOD | Blood samples for Canocapavir PK analysis were collected at different time points, and were collected and placed into a vacutainer with an anticoagulant (K | PMC10022191 | |
Antiviral activity | BLOOD | The changes in the serum levels of HBV DNA, HBV pgRNA, HBcrAg, HBsAg, HBsAb, HBeAg, HBeAb, and HBcAb at different time points were examined. Blood samples were collected on the initial screening day (baseline) and days 1, 8, 15, 22, 29, 43 ± 1, and 57 ± 2 postdosing. Blood samples for detecting viral resistance to Cano... | PMC10022191 | |
Statistical analysis | The following observed data were used for the analysis of the plasma PK parameters with the noncompartmental PK approach using WinNonlin, version 8.2, software (Pharsight Co., Mountain View, CA, USA): the maximum observed plasma concentration (Cmax), the time to maximum observed serum concentration (Tmax), area under t... | PMC10022191 | ||
Results | PMC10022191 | |||
Safety and tolerability | ADVERSE REACTIONS | This study showed that Canocapavir was safe and tolerated over the 28 days of treatment. No serious AE occurred during the period of the trial. No patients withdrew from the study due to an AE, thus allowing the tolerability, antiviral, and PK analyses on data from all patients. A total of 76.7% (23/30) of the patients... | PMC10022191 | |
Antiviral activity | DRUG WITHDRAWAL | The level of HBV DNA decreased profoundly from baseline in the patients receiving three doses of Canocapavir but not in those receiving placebo. The HBV DNA level decreased greatly starting from day 8, with the average maximum decrease on day 22 or day 29. The HBV DNA level gradually returned to the baseline after drug... | PMC10022191 | |
Discussion | CHB, HBV infection, liver decompensation, hepatomegaly, liver stiffness, hepatitis, steatosis, chronic disease | ADVERSE REACTIONS, VIRUS, LIVER DECOMPENSATION, LIVER CIRRHOSIS, ADVERSE REACTION, HEPATOCELLULAR CARCINOMA, LACTIC ACIDOSIS, HEPATITIS, STEATOSIS, CHB, CHRONIC DISEASE | In this phase 1b study, we examined the safety, tolerability, PK profiles, and preliminary clinical efficacy of Canocapavir, a novel CAM-E CpTA for the treatment of patients with CHB. Our results showed that Canocapavir was safe and well tolerated in patients with CHB, and serum HBV DNA and HBV pgRNA were profoundly re... | PMC10022191 |
Study limitation | This study does have some limitations that must be addressed in future studies. These include a small number of patients, a short treatment and follow-up period, and the lack of analysis of immune-inflammatory factors. These limitations will be addressed in future multicenter studies of Canocapavir in more patients wit... | PMC10022191 | ||
Conclusions | CHB | ADVERSE REACTIONS, VIRUS, CHB | Canocapavir was well tolerated. Most of the adverse reactions were grade I or II in severity. No dose-dependency was observed for either the frequency or intensity of AEs. Corresponding to 50–200-mg doses of Canocapavir, a linear PK profile and a low-to-mild accumulation rate (1.26–1.99) were notable. After oral dosing... | PMC10022191 |
Acknowledgements | This work was financially supported by the Capital Construction Funds within the provincial budget for 2020 (in the category of Innovation Capacity Construction, project number: 2020C038-1) and was also sponsored by Shanghai Zhimeng Biopharma, Inc. | PMC10022191 | ||
Authors’ contributions | HL | XJ, HC1, ZZ, HZ, JN, and YD designed the study. HJ, JM, MW, HC2, XL, CL, JL CL, YH, XZ, HZ, and YD performed the clinical trial. JM, HZ, JN, and YD analyzed the data. HJ, HZ, and YD wrote and edited the manuscript as well as composed the figures. BH, TX, GL, AD, BL, RG, HL, and ZW synthesized the drug and assisted in t... | PMC10022191 | |
Funding | This work was financially supported by the Capital Construction Funds within the provincial budget for 2020 (in the category of Innovation Capacity Construction, project number: 2020C038-1) and was also sponsored by Shanghai Zhimeng Biopharma, Inc. | PMC10022191 | ||
Availability of data and materials | The data that support the findings of this study are available on request from the corresponding authors after the completion of the study. The data are not publicly available due to privacy or ethical restrictions. | PMC10022191 | ||
Declarations | PMC10022191 | |||
Ethics approval and consent to participate | The study protocol was approved by the Institutional Review Board of the First Hospital of Jilin University, and conducted according to the Declaration of Helsinki, Guidelines for Good Clinical Practice, and local laws and regulations. The ethics approval number is 20Y201-006. All patients provided written informed con... | PMC10022191 | ||
Consent for publication | Not applicable. | PMC10022191 | ||
Competing interests | XJ, BH, TX, GL, AD, BL, RG, HL, ZW, HC, and ZZ are employees of Shanghai Zhimeng Biopharma, which sponsored this study. The other authors declare no conflicts of interest. | PMC10022191 | ||
References | PMC10022191 | |||
Objective | T2DM, P. | TYPE 2 DIABETES MELLITUS | Edited by: João P. Magalhães, University of Lisbon, PortugalReviewed by: Megan Hetherington-Rauth, Universidade de Lisboa, Portugal; Romeu Mendes, University Porto, PortugalThis article was submitted to Cardiovascular Endocrinology, a section of the journal Frontiers in EndocrinologyTo compare the effects of different ... | PMC9900112 |
Methods | T2DM | This study was a parallel clinical trial. Fifty-two men and women with T2DM (>40 years) were randomly allocated into three groups, and 44 (22 males/22 females) were included in the final analysis. Exercise intensity was based on the speed corresponding to the maximum oxygen consumption (v | PMC9900112 | |
Results | There was a significant difference between groups for changes on | PMC9900112 | ||
Conclusion | Low-volume HIIT promoted greater improvements in cardiorespiratory capacity in comparison with low-volume MICT, independent of the protocols used. There were no other differences between groups. All protocols improved at least one of the variables analyzed; however, the most evident benefits were after the high-intensi... | PMC9900112 | ||
Introduction | T2DM, disability | TYPE 2 DIABETES MELLITUS | Type 2 diabetes mellitus (T2DM) is one of the leading causes of disability worldwide (HIIT is a type of aerobic training that consists of performing high intensity exercise bouts alternated with passive or active recovery periods (Kilpatrick et al., (In this context, it is important to determine whether the use of diff... | PMC9900112 |
Material and methods | PMC9900112 | |||
Study design | T2DM | This study is a parallel randomized clinical trial that involved individuals with T2DM of both sex that performed different aerobic training protocols, two times per week for eight weeks. The study was performed at the Hospital of the Federal University of Goias (Goiania, Brazil), approved by the relevant Human Researc... | PMC9900112 | |
Participants | renal or liver failure, cardiovascular diseases, neoplasm, arrhythmias, hypothyroidism, T2DM, obstructive pulmonary disease | CARDIOVASCULAR DISEASES, HEART, UNSTABLE ANGINA, OBSTRUCTIVE PULMONARY DISEASE, EXTRASYSTOLES, NEOPLASM, DIABETES, ARRHYTHMIAS, HYPOTHYROIDISM, EYE | Sixty participants with T2DM were recruited from 3rd Diabetes Task Force promoted by the Eye Bank Foundation of Goiás. To be included in the study, participants had to be 40 years old or more, diagnosed with T2DM, have a fasting glycemia above 126 mg/dL and/or glycated hemoglobin greater than 6.4%, and to not participa... | PMC9900112 |
Medication record | Medication use was self-reported according to Class of medicines used by patients.HIIT, high-intensity interval training; MICT, moderate intensity continuous training; SGLT2, Sodium glucose cotransporter 2; DPP-4, Dipeptidyl peptidase-4; GLP-1, Glucagon-like peptide-1. | PMC9900112 | ||
Biochemical analyses | At the first visit to the laboratory, 4 mL of whole blood was collected by the vacuum method into EDTA tubes (Plastilab, Brazil) from the antecubital vein after approximately 12 h overnight fasting. Homogenized whole blood was used for preparation and processing of samples.The following analyzes were performed for gluc... | PMC9900112 | ||
Cardiopulmonary exercise test (CPET) | RPE | HEART | CPET involved an incremental ramp type protocol performed on a treadmill (MicromedAfter warm-up, treadmill speed was set according to age and gender, following the recommendations of the Brazilian Society of Cardiology. The speed was then increased by 0.1 km/h every 10, 20 or 30 seconds until voluntary exhaustion, and ... | PMC9900112 |
Exercise protocols | The protocols were customized with individualized monitored of HR, BP and v Exercise session started with a 2 min warm-up and ended with a 2 min cooldown at 50% of v Exercise intensity was adjusted using perceived of exertion as previously suggested ( | PMC9900112 | ||
Statistical analyses | Data normality and homogeneity were tested using the Shapiro-Wilk and Levene test, respectively. Post-training values were compared between groups using analysis of covariance (ANCOVA) with pre-training values as covariates. When a significant effect was identified, All analyses were performed using SPSS statistical pa... | PMC9900112 | ||
Results | ±, S-HIIT, high-density lipoprotein | The characteristics of participants are described in Characteristics of participants.BMI, body mass index; training; S-HIIT, short high-intensity interval training; L-HIIT, long high-intensity interval training; MICT, moderate intensity continuous; M, Male; F, Female. Data presented as mean ± standard deviation.There w... | PMC9900112 | |
Discussion | S-HIIT, reductions in cardiovascular events, BP reductions, T2DM, dyslipidemia | CARDIOVASCULAR DISEASES, DYSLIPIDEMIA | The present study investigated the effects of three aerobic training protocols (L- HIIT, S-HIIT, and MICT) on cardiometabolic parameters of patients with T2DM. The recommendation of a minimum of 150 min per week of moderate intensity physical activities for blood glucose control and cardiovascular health is still predo... | PMC9900112 |
Conclusion | Low-volume HIIT promoted greater improvements in cardiorespiratory capacity in comparison with low-volume MICT, independent of the protocols used. There were no other difference between groups. All protocols improved at least one of the variables analyzed; however, the most evident benefits were after the high-intensit... | PMC9900112 | ||
Data availability statement | The raw data supporting the conclusions of this article will be made available by the authors, under reasonable request. | PMC9900112 | ||
Ethics statement | The studies involving human participants were reviewed and approved by Federal University of Goias Ethics Committee. The patients/participants provided their written informed consent to participate in this study. | PMC9900112 | ||
Author contributions | PG conceived and designed the research. LS, JC, and JSC performed experiments. DS and PG analyzed data, interpreted results of experiments, and drafted manuscript. DS and AR edited and revised manuscript. All authors contributed to the article and approved the submitted version. | PMC9900112 | ||
Acknowledgments | We would like to thank all participants who volunteered their time to participate in the study. | PMC9900112 | ||
Conflict of interest | The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. | PMC9900112 | ||
Publisher’s note | All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or ... | PMC9900112 | ||
References | PMC9900112 | |||
Subject terms | sepsis, septic | ADVERSE EVENTS, SEPSIS | Patients with sepsis often require emergency intubation. In emergency departments (EDs), rapid-sequence intubation with a single-dose induction agent is standard practice, but the best choice of induction agent in sepsis remains controversial. We conducted a randomized, controlled, single-blind trial in the ED. We incl... | PMC10115773 |
Introduction | sepsis, Sepsis | SEPSIS, SEPSIS | Sepsis is a major medical emergency in emergency departments (EDs) and has a high rate of morbidity and mortalityEtomidate is a nonbarbiturate hypnotic that is most often used in RSIKetamine is an alternative induction agent in sepsis. It increases blood pressure and heart rate through catecholamine release and is cons... | PMC10115773 |
Methods | PMC10115773 | |||
Trial design and oversight | EMERGENCY | From March 2019 to December 2020, this single-centre, randomized, single-blind, controlled trial, with 1:1 allocation, was conducted by the Emergency Medicine Research Group at Thammasat University Hospital (TUH) in Pathum Thani, Thailand. TUH is an 800-bed tertiary academic teaching hospital in the suburbs north of Ba... | PMC10115773 | |
Ethics approval and consent to participate | The trial was approved by the Human Research Ethics Committee of the Faculty of Medicine of Thammasat University. Because of the sudden and life-threatening nature of cases in patients who needed emergency intubation, the process of obtaining written informed consent was deferred until after the emergency had passed. W... | PMC10115773 | ||
Trial registration | The trial protocol was registered in the Thai Clinical Trials Registry (identification number; TCTR20210213001). Registered 13 February 2021—Retrospectively registered, | PMC10115773 | ||
Patient population | sepsis, hypertension, cardiac arrest | ADRENAL INSUFFICIENCY, SEPSIS, HYPERTENSION, CARDIAC ARREST | Patients presenting to the ED with suspected sepsis who were 18 years or older and then needed an induction agent for emergency intubation in the ED were eligible for inclusion. Exclusion criteria were as follows: (1) cardiac arrest before intubation, (2) presence of a do-not-resuscitate order, (3) known or suspected a... | PMC10115773 |
Randomization and treatment | sepsis, Sepsis, Septic Shock | SEPSIS, SEPSIS, RSI, SEPTIC SHOCK | Patients were randomly assigned to receive a single-dose induction agent consisting of either etomidate (Lipuro, B. Braun Melsungen, Germany) administered as a 0.2–0.3 mg/kg intravenous bolus or ketamine (Ketalar, PAR Pharmaceutical, Ireland) administered as a 1–2 mg/kg intravenous bolus. The randomization sequence was... | PMC10115773 |
Outcomes | peri-intubation adverse, hypotension, cardiac arrest | ADVERSE EVENTS, SECONDARY, CARDIAC ARREST | The primary outcome was 28-day survival. The secondary outcomes were 24-h survival, 7-day survival, early haemodynamic parameters after intubation, amount of fluid required in the first three hours, and occurrence of peri-intubation adverse events. Peri-intubation adverse events included cardiac arrest (during or immed... | PMC10115773 |
Sample size estimation | A pilot study was performed to obtain the preliminary data for the calculation of a sample size for the primary outcome. Our power was determined by the survival rate of the pilot population. We determined that a group of 130 patients in the etomidate allocation and a group of 130 patients in the ketamine allocation we... | PMC10115773 | ||
Statistical analysis | The independent data monitoring committee performed an interim analysis every 6 months. We used the Haybittle-Peto boundary to determine the upper and lower stopping boundaries for the primary outcome, with no adjustment in the final analysis.The survival outcomes were analysed without adjustment in the intention-to-tr... | PMC10115773 | ||
Results | PMC10115773 | |||
Patients and interventions | sepsis | SEPSIS, HIGH BLOOD PRESSURE | A total of 272 suspected sepsis patients who needed an induction agent for emergency intubation were enrolled. 12 patients were excluded because of very high blood pressures before intubation (Fig. Flow diagram of the study patients enrolled.Characteristics of the patients at baseline.Intubation conditions between the ... | PMC10115773 |
Primary and secondary outcomes | postintubation hypotension, peri-intubation adverse, cardiac arrest | SECONDARY, CARDIAC ARREST | In the etomidate group, 105 patients (80.8%) were alive at 28 days compared to 95 patients (73.1%) in the ketamine group (risk difference [RD], 7.7%; 95% confidence interval [CI], − 2.5 to 17.9%; P = 0.092). There were no significant differences between the etomidate group and the ketamine group in the proportion of pa... | PMC10115773 |
Discussion | critically ill, peri-intubation adverse, peri-intubation, peri-intubation cardiac arrest, hypotension, ill, sepsis | ADVERSE EVENTS, SEPSIS, CRITICALLY ILL | The main goal of this study was to compare the clinical outcomes between the two induction agents that are most commonly used for emergency intubation in EDs. We found no significant differences in survival at 24 h, 7 days, and 28 days in sepsis patients intubated with etomidate or ketamine. We also found no significan... | PMC10115773 |
Limitations | hypotension | Our study was limited by its sample size, and although our results show no difference in patients’ physiological parameters and postintubation hypotension after a single-dose of etomidate or ketamine, we had limited statistical power. Moreover, we did not calculate the sample size to demonstrate the differences in phys... | PMC10115773 | |
Conclusions | sepsis | SEPSIS | In patients with clinically suspected sepsis who needed emergency intubation in the ED, there was no difference in early and 28-day survival rates between etomidate and ketamine. However, etomidate was associated with higher risks of early vasopressor use after intubation. | PMC10115773 |
Author contributions | Conceptualization: W.S., A.B., K.A. Protocol development: W.S., K.A. Data collection: A.B., K.D., C.L., K.A., I.I., N.D., I.D., Y.S., T.U., C.P. Data analysis: W.S., A.B. Writing and editing manuscript: W.S., V.P. All authors read and approved the final manuscript. | PMC10115773 | ||
Funding | EMERGENCY | This study is funded by the Research group in Emergency Medicine and Emergency Critical Care of the Faculty of Medicine of Thammasat University. | PMC10115773 | |
Data availability | The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. | PMC10115773 | ||
Competing interests | The authors declare no competing interests. | PMC10115773 | ||
References | PMC10115773 | |||
Background | depression, anxiety | Growing evidence suggests a role for gut bacteria and their metabolites in host-signaling responses along the gut-brain axis which may impact mental health. Meditation is increasingly utilized to combat stress, anxiety, and depression symptoms. However, its impact on the microbiome remains unclear. This study observes ... | PMC10074366 | |
Methods | There were 288 subjects for this study. Stool samples were collected at 3-time points for meditators and household controls. Meditators prepared for 2 months for the Samyama, incorporating daily yoga and meditation practices with a vegan diet including 50% raw foods. Subjects were requested to submit stool samples for ... | PMC10074366 | ||
Results | Alpha diversity showed no significant differences between meditators and controls, while beta diversity showed significant changes (padj = 0.001) after Samyama in meditators’ microbiota composition. After the preparation phase, changes in branched short-chain fatty acids, higher levels of iso-valerate (padj = 0.02) and... | PMC10074366 | ||
Conclusion | This study examined the impact of an advanced meditation program combined with a vegan diet on the gut microbiome. There was an increase in beneficial bacteria even three months after the completion of the Samyama program. Further study is warranted to validate current observations and investigate the significance and ... | PMC10074366 | ||
Trial registration | Registration number: | PMC10074366 | ||
Keywords | PMC10074366 | |||
Background | depression, anxiety | Understanding the influence of the gut microbiota on nervous system function is gaining increasing interest from the scientific community [The human gut microbiota influences emotional and psychological states in a bidirectional way. Recent evidence points to the microbiome as part of a neuro-immune-endocrine matrix [O... | PMC10074366 | |
Materials and methods | PMC10074366 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.